High-sensitivity cardiac troponin levels were strongly associated with the risk for incident heart failure, according to a meta-analysis published in JACC: Heart Failure. Jonathan D. W. Evans, M.B., Ch.B., BHF Cambridge CRE clinical research training fellow in the Department of Public Health and Primary Care at the University of Cambridge, and colleagues analyzed the data in a summary published in Healio.
Based on the results, preliminary data showing discrimination improvements in heart failure risk with high-sensitivity cardiac troponin assessment suggest that it may be a promising biomarker for measurement as part of primary prevention of heart failure.
According to a related editorial from Allan Jaffe, M.D., Consultant and Chair of Mayo Clinic’s Division of Clinical Core Laboratory Services, with a joint appointment in the Division of Cardiovascular Diseases, and Wayne Miller, M.D., Ph.D., Professor in the Department of Cardiovascular Medicine at Mayo Clinic, the physicians stated, "As advocates for biomarker use in patients with heart failure and from our previous studies, we appreciate the interesting proof of concept presented by Evans, et al., and with which we concur in regard to establishing estimates of those at risk for heart failure going forward. However, we also have tried to use this opportunity to suggest that the field needs to spend additional time and effort refining the specific techniques that might more fully optimize the ability to use summary and meta-analyses that include biomarkers."